- Home
- ELF vs ROIV Comparison
ELF vs ROIV Comparison
Compare ELF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELF
- ROIV
- Stock Information
- Founded
- ELF 2004
- ROIV 2014
- Country
- ELF United States
- ROIV United Kingdom
- Employees
- ELF N/A
- ROIV N/A
- Industry
- ELF Package Goods/Cosmetics
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ELF Consumer Discretionary
- ROIV Health Care
- Exchange
- ELF Nasdaq
- ROIV Nasdaq
- Market Cap
- ELF 6.9B
- ROIV 7.8B
- IPO Year
- ELF 2016
- ROIV N/A
- Fundamental
- Price
- ELF $110.57
- ROIV $11.40
- Analyst Decision
- ELF Buy
- ROIV Buy
- Analyst Count
- ELF 16
- ROIV 4
- Target Price
- ELF $121.44
- ROIV $17.50
- AVG Volume (30 Days)
- ELF 1.9M
- ROIV 7.9M
- Earning Date
- ELF 08-07-2025
- ROIV 08-07-2025
- Dividend Yield
- ELF N/A
- ROIV N/A
- EPS Growth
- ELF N/A
- ROIV N/A
- EPS
- ELF 1.92
- ROIV N/A
- Revenue
- ELF $1,313,517,000.00
- ROIV $29,053,000.00
- Revenue This Year
- ELF $22.42
- ROIV $3.28
- Revenue Next Year
- ELF $15.80
- ROIV $156.84
- P/E Ratio
- ELF $57.28
- ROIV N/A
- Revenue Growth
- ELF 28.28
- ROIV N/A
- 52 Week Low
- ELF $49.40
- ROIV $8.73
- 52 Week High
- ELF $219.77
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- ELF 42.65
- ROIV 54.55
- Support Level
- ELF $113.88
- ROIV $10.71
- Resistance Level
- ELF $132.48
- ROIV $11.58
- Average True Range (ATR)
- ELF 5.17
- ROIV 0.29
- MACD
- ELF -3.21
- ROIV 0.00
- Stochastic Oscillator
- ELF 0.32
- ROIV 62.16
About ELF e.l.f. Beauty Inc.
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.